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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
collagenase clostridium histolyticum is a safe and effective treatment for adult patients with
Dupuytren’s contracture.
STUDY DESIGN: Review of two double-blind, placebo-controlled randomized controlled trials
and one cross-sectional study. All of these studies are published in English between 2009-2013.
DATA SOURCES: Two double-blind, placebo-controlled randomized controlled trials and one
cross-sectional study found using PubMed.
OUTCOMES MEASURED: Each randomized controlled trial measured the ability to meet the
primary end point and all secondary endpoints, percent decrease in degree of contracture,
increase in range of motion, patient satisfaction, and recording of adverse events which played a
significant role in patient quality of life.
RESULTS: Hurst et al and Gilpin et al showed a significant increase in range of motion and
decrease in the flexion contracture after the use of collagenase clostridium histolyticum
compared to the placebo. The NNT for Hurst et al was 2 while the NNT for Gilpin et al was 3.
There were significantly more adverse effects in the collagenase group than placebo group such
as contusion and injection site hemorrhage or pain. Hay et al found surgery was made more
difficult in 4 out of 15 (26.7%) cases compared to the other 11 out of 15 (73.3%) cases in which
surgery was not made more difficult.
CONCLUSIONS: Based on these three studies, collagenase clostridium histolyticum is a safe
and effective treatment for adults with Dupuytren’s contracture. The studies exhibited significant
improvement in range of motion and decreasing the flexion contractures involved in
Dupuytren’s.
KEY WORDS: Collagenase clostridium histolyticum, Dupuytren’s contracture
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INTRODUCTION
Dupuytren’s contracture is a disorder in which collagen is produced in excess amounts
and is deposited in the palmar aspect of the hands surrounding the tendons. With time, thick
cords form and lengthen down the hand which leads to flexion contractures. These flexion
contractures greatly limit the hand’s ability to function. 1 This paper evaluates two double-blind,
placebo-controlled trials and a cross-sectional study comparing the safety and efficacy of
collagenase clostridium histolyticum in adult patients with Dupuytren’s contracture.
Dupuytren’s contracture is relevant to the physician assistant profession and to patients
because of its incidence, cost, and effect on a patient’s quality of life. The incidence of
Dupuytren’s contracture is 4% in the United States2 and 3-6% of whites globally.1 The cost for
the fasciectomy surgical procedure which has historically been the standard of care treatment for
Dupuytren’s contracture is $2102.56 while the cost for the collagenase clostridium histolyticum
injection is $1418.04, which makes the injection form of treatment cost 33% less than the
fasciectomy.3
While the underlying etiology of Dupuytren’s contracture is unknown, genetics are
thought to play a role since a positive family history is common in patients with Dupuytren’s
contracture.2 Recurrence is a common process with Dupuytren’s contracture no matter the
treatment. Recurrence usually occurs as a slow process over a few years.
There are different treatment modalities for Dupuytren’s contracture. Dupuytren’s
contracture can be treated via needle aponeurotomy, open fasciectomy/fasciotomy surgical
procedures, or via collagenase clostridium histolyticum injection.4 Currently, the standard of care
for Dupuytren’s contracture is an open fasciectomy. Collagenase clostridium histolyticum is
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being proposed as a new treatment because it is less invasive, carries less risk than the surgical
option, and is more cost-effective than an open fasciectomy.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not collagenase
clostridium histolyticum is a safe and effective treatment for adult patients with Dupuytren’s
contracture.
METHODS
The population in the 2 randomized, double-blind, placebo-controlled trials and 1 crosssectional article utilized in this review includes adult patients with Dupuytren’s contracture. The
intervention for the treatment group was 0.58 mg collagenase clostridium histolyticum injection.
The comparison used in patients who were in the control group was a placebo injection of 10mM
tris plus 60mM sucrose. The outcomes measured were the safety and efficacy of collagenase
clostridium histolyticum which were measured by the ability to meet the primary and all
secondary endpoints, increase in range of motion, recording of adverse events, and surveys on
the distortion of anatomy completed by surgeons who performed open fasciectomy procedures
on recurrent Dupuytren’s cords after previously receiving collagenase clostridium histolyticum.
All of these have a significant effect on the quality of life for patients.
Keywords used in searches for these articles on PubMed were Dupuytren’s disease,
clostridial collagenase, Dupuytren’s contracture, collagenase clostridium histolyticum, and
Dupuytren’s. The articles chosen were published in English. Inclusion criteria used for selection
of the patients in these studies were healthy males and female over age 18 with Dupuytren’s
contracture, women who were either postmenopausal or used contraception,
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metacarpophalyngeal (MCP) contractures between 20ᵒ and 100ᵒ or proximal interphalangeal
(PIP) contractures between 20ᵒ and 80ᵒ, and the inability to place affected finger and palm flat on
a table at the same time. Exclusion criteria included women who were breastfeeding or pregnant,
people with bleeding disorders, recent stroke, previous treatment to the affected digit within 90
days, use of a tetracycline derivative within 14 days, anticoagulant within 7 days, allergy to
collagenase, or anyone with chronic muscle, neurologic, or neuromuscular disorder that affects
the hands. The author searched the articles via PubMed and selected them based on their
relevance to the safety and efficacy of collagenase clostridium histolyticum and if the articles
included outcomes that matter to patients. The statistics reported or used in the articles were
relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT),
confidence interval (CI), and p-values. Table 1 displays the above mentioned information.
Table 1- Demographics & Characteristics of included studies
Study

Type

Hurst 1
(2009)

Double
blind
RCT

#
Pts
308

Age
(yrs)
62.7
+/- 9.5

Inclusion
criteria
Patients over
18, women
who were
either
postmenopaus
al or used
contraception,
MCP
contractures
between 20ᵒ
and 100ᵒ or
PIP
contractures
between 20ᵒ
and 80ᵒ,
inability to
put finger and
palm flat on
table at same
time

Exclusion criteria

W/D

Pregnant or
2
breastfeeding women,
bleeding disorders,
recent stroke,
previous treatment
within 90 days of
affected finger, use of
tetracycline
derivative within 14
days of study, use of
anticoagulant within
7 days of study,
allergy to
collagenase, patients
with chronic muscle,
neurologic, or
neuromuscular
disease to hands

Interventions
0.58 mg
collagenase
clostridium
histolyticum
plus 0.25 mL
sterile diluent
for MCP
joints or 0.20
mL sterile
diluent for
PIP joints
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Gilpin4
(2010)

Double
blind
RCT

Hay5
(2013)

Cross
15
sectional

66

63.8
+/- 9.0

n/a

Patients over
18, women
who were
either
postmenopaus
al or used
contraception,
MCP
contractures
between 20ᵒ
and 100ᵒ or
PIP
contractures
between 20ᵒ
and 80ᵒ,
inability to
put finger and
palm flat on
table at same
time
Adult patients
with
Dupuytren’s
contracture
recurrence
after a
previous
collagenase
clostridium
histolyticum
injection

Pregnant or
2
breastfeeding women,
bleeding disorders,
recent stroke,
previous treatment
within 90 days of
affected finger, use of
tetracycline
derivative within 14
days of study, use of
anticoagulant within
7 days of study,
allergy to
collagenase, patients
with chronic muscle,
neurologic, or
neuromuscular
disease to hands

0.58 mg
collagenase
clostridium
histolyticum
+ lyophilized
tris + sucrose

Adult patients with
Dupuytren’s
contracture with no
prior treatment with
collagenase
clostridium
histolyticum

n/a

0

OUTCOMES MEASURED
The outcomes measured include ability to meet the primary end point and all secondary
endpoints, percent decrease in degree of contracture, increase in range of motion, and recording
of adverse events. The primary end point was a reduction of the joint contracture to 0-5ᵒ of full
extension by day 30 post-injection. Secondary end points were two different times used to
compare recurrence of the contracture. These two times were 30 days after the first injection and
30 days after the last injection. 1,4
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Changes in range of motion were measured by using the finger goniometry technique.
These angles were measured during screening prior to starting the treatments, during treatment,
and 90 days after treatment. To monitor safety and adverse events, patients were monitored for
60 minutes after the injection. In addition, their vital signs were monitored before injection, for
60 minutes following injection, on days 1, 7, 30, and 90. Blood and urine samples were obtained
at screening, 30 and 90 days after injection.1
RESULTS
Hurst et al1 and Gilpin et al4, both double-blind placebo-controlled randomized controlled
trials evaluated the safety and efficacy of collagenase clostridium histolyticum on Dupuytren’s
contractures by comparing experimental groups to control groups. The experimental groups
received the collagenase clostridium histolyticum injection into the affected anatomy whereas
the control groups received a placebo injection into the affected anatomy.
Hay et al5, a cross sectional study examined the distortion of anatomy in the area
collagenase clostridium histolyticum was injected in patients who had recurrence of Dupuytren’s
contracture after receiving the injection. The study gathered information by surveying surgeons
performing the open fasciectomy on these patients who received the collagenase clostridium
histolyticum injection previously.
Table 2. Efficacy of collagenase clostridium histolyticum in the treatment of Dupuytren’s
contracture
Study
Hurst1 (2009)

Relative
Benefit
Increase (RBI)
8.41

Absolute
Benefit
Increase (ABI)
0.572

Number
Needed to
Treat (NNT)
2 patients

P-value

<0.001

Confidence
Interval
(CI)
95%
(primary
end point)
99%
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Gilpin4 (2010) 8.25
Hay5 (2013)
n/a

0.396
n/a

3 patients
n/a

<0.001
n/a

(secondary
end point)
n/a
n/a

Table 3. Comparison of MCP and PIP range of motion (ROM) before and after treatment
Study
Hurst1 (2009)
Gilpin4 (2010)
Hay5 (2013)

MCP ROM
before treatment
43ᵒ
40ᵒ
n/a

MCP ROM after
treatment
84ᵒ
80ᵒ
n/a

PIP ROM before
treatment
46ᵒ
41ᵒ
n/a

PIP ROM after
treatment
75ᵒ
73ᵒ
n/a

Hurst et al1 evaluated the efficacy in numerous ways. The collagenase group met the
primary and secondary end points significantly more than the placebo group (p<0.002). In
addition, contractures were returned to 0-5ᵒ of full extension in 64% of joints in the collagenase
group compared to 6.8% in the placebo group. Most of the joints in the collagenase group that
did not meet the primary or secondary end points did not receive all of the injections. The most
common reason for this was that there was no palpable cord present. Table 3 illustrates the
change in range of motion before and after treatment with collagenase clostridium histolyticum.
A median of 56 days was required to attain the primary end point. Out of all the joints that met
the primary end point, none had recurrence by day 90.1
Additionally, 96.6% of patients who received the collagenase injection experienced at
least 1 adverse effect compared to 21.2% in the placebo group. Significantly more injection and
manipulation-related events such as contusion, injection site hemorrhage, injection site pain,
pain in upper extremity, tenderness, ecchymosis, injection site swelling, pruritis, skin laceration,
LN enlargement and pain on palpation, lymphadenopathy, erythema, blister, injection-site
pruritis and axillary pain were noted in the collagenase group ( p< or equal to 0.02). Most were
mild to moderate in severity and resolved without intervention within a median of 10 days. Of
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note, 20 patients in experimental group and 2 in placebo group experienced severe reactions such
as peripheral edema, injection site pain or hemorrhage, contusion, tenderness, or tendon rupture.
There were no deaths or nerve injuries reported.1 Therefore, the NNT was calculated as 2 (Table
2), which means that for every 2 patients treated with collagenase clostridium histolyticum, one
more patient will have improvement of their condition compared to the control.
In the 12 month double-blind phase of Gilpin et al4, the collagenase-injected group
experienced significantly reduced contractures compared to the placebo group (44.4% reduction
vs 4.8% reduction, p<0.001). In the experimental group, it took a mean of 57 days to reach the
primary end point and a mean of 1.5 injections. Most of the joints in the collagenase group that
did not meet the primary end point did not receive 3 injections into the affected cord, most often
because there was “no palpable cord to inject.”4 When analyzing data from the entire 12 month
study, 134 Dupuytren’s cords were injected with collagenase. From those, 62 were MCP joint
cords and 72 were PIP joint cords. Additionally, 42 of the 62 (67.7%) MCP joints and 26 of 72
(36.1%) PIP joints had a reduction in contracture after the last injection. 4
Recurrence was defined in the study as an increase in joint contracture to 20ᵒ or greater in
the presence of a palpable cord at any time during the study in joints that had a reduction in
contracture to 0ᵒ to 5ᵒ of normal. No joint met these criteria by the end of the study, which lasted
for 12 months.4
Gilpin et al4 measured safety by noting the adverse events experienced by the patients.
All (100%) of the patients who got the collagenase injection reported at least one adverse effect
compared to 8 out of 21 (38%) patients in the placebo group. Patients who were injected with
collagenase had significantly higher rates of edema, contusion, extremity pain, injection site pain
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or hemorrhage, and lymphadenopathy compared to the placebo group (p<0.05). Most adverse
effects were mild or moderate and resolved within a median of 8-10 days. One serious adverse
effect experienced by a patient was a flexion pulley rupture. No arterial, nerve, or tendon injuries
were reported during the 12 month study.4 The NNT was calculated as 3 (Table 2) which means
that for every 3 patients treated with collagenase clostridium histolyticum, one more patient will
have improvement in their condition compared to the control.
Hay et al presented the results as continuous data in the form of 5 grades which
represented the level of difficulty in performing open surgical procedures on patients who
received the collagenase clostridium histolyticum injection previously. Grade 1 was defined as
easier than a primary operation. Grade 2 was equivalent to a primary operation in difficulty.
Grade 3 was harder than a primary operation, grade 4 was equivalent to a revision operation, and
grade 5 was harder than a revision operation. Out of 15 cases, 9 were rated as grades 1 or 2 of
difficulty. Additionally, 2 cases were grade 4 difficulty and 4 cases were rated as grade 5
difficulty.5
For ease of understanding, these results were converted to dichotomous data in this
review. The data was converted into the following two groups: surgery was made more difficult
as a result of the collagenase clostridium histolyticum and surgery was not made more difficult
as a result of the collagenase clostridium histolyticum injection. Surgery was made more difficult
in 4 out of 15 (26.7%) cases compared to the other 11 out of 15 (73.3%) cases in which surgery
was not made more difficult from the collagenase injection. The respondents described the
findings of anatomy in the 4 cases which were more difficult. The anatomy was described as
“thick” and “hard” scars that made dissecting difficult.5
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DISCUSSION
Collagenase clostridium histolyticum is FDA approved for the treatment of Dupuytren’s
contracture and for men age 18 and older, Peyronie’s disease.6 Often any new product requires
an extended period of time for health care providers to integrate it into their practice.
Subsequently, it is much easier to find a healthcare provider who uses collagenase clostridium
histolyticum in an urban setting compared to a rural area due to the prevalence of physicians.
This is improving with time. In addition, while collagenase clostridium histolyticum is more
affordable than the open fasciectomy, it is still expensive if insurance fails to cover it or if a
patient is uninsured. This is another potential barrier to care. The sponsor of clostridium
collagenase histolyticum, Auxilium Pharmaceuticals, offers a co-pay reimbursement program
and a patient assistance program which may help deflect some of the cost if a patient qualifies. It
is important to note that collagenase clostridium histolyticum is contraindicated in patients who
have a history of hypersensitivity to collagenase. Additionally, since these studies were
performed on adults age 18 and over, it is not known if collagenase clostridium histolyticum is
safe to use in patients under age 18.6
Gilpin et al4 highlights the importance of continued follow-up over the next several years
with patients in the study to monitor the affected cord. Hurst et al1 expressed the importance in
assessing patient compliance with wearing custom fitted splints after the injection every night for
up to 4 months. Hay et al5 noted the importance of evaluating more patients but explained there
are a limited number of patients who have undergone surgery after receiving collagenase
injections which limited their study. Hay et al5 also noted the potential of subjectivity in the
responses from the healthcare providers they surveyed as well as the subjectivity of noting
distortion of anatomy during the surgeries performed.
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CONCLUSION
Based on this systematic review of the chosen studies, collagenase clostridium
histolyticum is a safe and effective treatment for adult patients with Dupuytren’s contracture.
The data in these studies represents the efficacy and safety of collagenase clostridium
histolyticum. Future areas of study in long-term follow up would be beneficial to monitor
continued patient satisfaction and recurrence. Additionally, it would be beneficial to include
larger sample sizes in future studies.
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